country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-181983

Copy Link Print Information

VPC285785

VPC285785 is an orally active SARS-CoV-2 main protease inhibitor with an IC₅₀ of 0.8 μM and a K_d of 2.7 μM. VPC285785 functionally inhibits the viral main protease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2759276-10-1
Formel: C₂₄H₂₅F₂N₅O₃
Molecular Weight:469.48

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

VPC285785 Chemical Structure

CAS. Nr.: 2759276-10-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

VPC285785 (10 μM) exerts weak inhibitory effects on human cathepsin L (CatL), with only 15% inhibition observed at the concentration of 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	AUC_last	AUC_0-inf	T_1/2	V_z	T_max	Bioavailability
Mice^[1]	10 mg/kg	i.v.	18700 ng/mL	16.833 μg·h/mL	17 μg·h/mL	36.5 min	0.5 L/kg	/	/
Mice^[1]	10 mg/kg	p.o.	953 ng/mL	2.433 μg·h/mL	149 μg·h/mL	2.48 min	/	30 min	15 %

In Vivo

VPC285785 (150 mg/kg; p.o.; once daily; for 3 consecutive days) significantly reduces viral loads in the liver, brain and spleen of MHV-A59-infected mice while preserving their liver and kidney functions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/CJ (female, 8-10 weeks old, 18.5-26.5 g, intranasal infection with MHV-A59)^[1]
Dosage:

150 mg/kg
Administration:

p.o.; once daily; 3 days (day 1, 2, 3 post-infection)
Result:

Reduced liver enzyme levels: alanine transaminase (ALT) 65.5 U/L, aspartate aminotransferase (AST) 126.0 U/L, and total protein (TP) 54.16 g/L.
Showed less pronounced decrease in blood urea nitrogen (BUN) levels.
Lowered white blood cell (WBC) counts.
Achieved statistically significant reduction in viral load in the liver, brain, and spleen; no significant differences in viral load observed in the lung, heart, or kidney.

Chemical Information

CAS. Nr. 2759276-10-1
Molecular Weight 469.48
Formel C₂₄H₂₅F₂N₅O₃
SMILES

FC1=CC(F)=C(C=C(C(N2C[C@H](C3(C)C)[C@H]3[C@H]2C(N[C@H](C#N)C[C@@H]4CCNC4=O)=O)=O)N5)C5=C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Smith JR, et al. Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection. Sci Rep. 2026 Feb 2;16(1):6905. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen